Available to sourceHuman Prescription DrugOncology & Specialty

Everolimus

.25 mg/1 · Tablet

By Par Health USA, LLC

NDC: 49884-158
Route: Oral
Therapeutic class: Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor , Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant , mTOR Inhibitors [MoA]
Marketing category: ANDA

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Related in Oncology & Specialty

See all →

Everolimus

Additional information

Request this medication

Related in Oncology & Specialty

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)

Verzenio (abemaciclib)